<DOC>
	<DOCNO>NCT02932891</DOCNO>
	<brief_summary>An Open Label , Safety Study Assess Potential Adrenal Suppression Following Treatment DSXS Patients Atopic Dermatitis</brief_summary>
	<brief_title>An Open Label , Safety Study Assess Potential Adrenal Suppression .</brief_title>
	<detailed_description>To evaluate potential DSXS topical product suppress HPA axis function patient moderate severe atopic dermatitis .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Parent/legal guardian sign informed consent form , meet criteria current FDA regulation . Females pregnant , nursing , plan become pregnant duration study , childbearing potential sexually active prepare use appropriate contraceptive method avoid pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>